Published in Hepatitis Weekly, October 1st, 2007
The significance of this data lies in the fact that CEL-1000 appears to be able to mount a faster immune response, something...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.